Alnylam Pharmaceuticals (ALNY) Revenue & Revenue Breakdown
Alnylam Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$1.83B
Latest Revenue (Q)
$659.83M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Alnylam Pharmaceuticals Revenue by Period
Alnylam Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.83B | 76.23% |
| 2022-12-31 | $1.04B | 22.88% |
| 2021-12-31 | $844.29M | 71.31% |
| 2020-12-31 | $492.85M | 124.28% |
| 2019-12-31 | $219.75M | 193.36% |
| 2018-12-31 | $74.91M | -16.69% |
| 2017-12-31 | $89.91M | 90.66% |
| 2016-12-31 | $47.16M | 14.75% |
| 2015-12-31 | $41.10M | -18.72% |
| 2014-12-31 | $50.56M | 7.20% |
| 2013-12-31 | $47.17M | -29.31% |
| 2012-12-31 | $66.72M | -19.37% |
| 2011-12-31 | $82.76M | -17.28% |
| 2010-12-31 | $100.04M | -0.49% |
| 2009-12-31 | $100.53M | 4.54% |
| 2008-12-31 | $96.16M | 88.94% |
| 2007-12-31 | $50.90M | 89.00% |
| 2006-12-31 | $26.93M | 371.13% |
| 2005-12-31 | $5.72M | 33.61% |
| 2004-12-31 | $4.28M | 2330.68% |
| 2003-12-31 | $176.00K | 100.00% |
| 2002-12-31 | - | - |
Alnylam Pharmaceuticals generated $1.83B in revenue during NA 2023, up 76.23% compared to the previous quarter, and up 2440.72% compared to the same period a year ago.
Alnylam Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $659.83M | 33.48% |
| 2024-03-31 | $494.33M | 12.42% |
| 2023-12-31 | $439.72M | -41.41% |
| 2023-09-30 | $750.53M | 135.46% |
| 2023-06-30 | $318.75M | -0.17% |
| 2023-03-31 | $319.29M | -4.70% |
| 2022-12-31 | $335.04M | 26.76% |
| 2022-09-30 | $264.31M | 17.56% |
| 2022-06-30 | $224.82M | 5.42% |
| 2022-03-31 | $213.26M | -17.51% |
| 2021-12-31 | $258.54M | 37.79% |
| 2021-09-30 | $187.63M | -14.93% |
| 2021-06-30 | $220.55M | 24.21% |
| 2021-03-31 | $177.57M | 8.56% |
| 2020-12-31 | $163.56M | 29.96% |
| 2020-09-30 | $125.85M | 21.06% |
| 2020-06-30 | $103.96M | 4.51% |
| 2020-03-31 | $99.48M | 38.78% |
| 2019-12-31 | $71.68M | 2.31% |
| 2019-09-30 | $70.06M | 56.69% |
| 2019-06-30 | $44.71M | 34.30% |
| 2019-03-31 | $33.29M | 58.29% |
| 2018-12-31 | $21.03M | 916.58% |
| 2018-09-30 | $2.07M | -93.08% |
| 2018-06-30 | $29.91M | 36.57% |
| 2018-03-31 | $21.90M | -42.26% |
| 2017-12-31 | $37.92M | 121.83% |
| 2017-09-30 | $17.10M | 7.31% |
| 2017-06-30 | $15.93M | -15.97% |
| 2017-03-31 | $18.96M | 8.63% |
| 2016-12-31 | $17.45M | 27.86% |
| 2016-09-30 | $13.65M | 56.75% |
| 2016-06-30 | $8.71M | 18.57% |
| 2016-03-31 | $7.34M | -2.73% |
| 2015-12-31 | $7.55M | 19.40% |
| 2015-09-30 | $6.32M | -27.18% |
| 2015-06-30 | $8.69M | -53.15% |
| 2015-03-31 | $18.54M | -22.82% |
| 2014-12-31 | $24.02M | 118.91% |
| 2014-09-30 | $10.97M | 50.40% |
| 2014-06-30 | $7.29M | -11.84% |
| 2014-03-31 | $8.28M | -23.71% |
| 2013-12-31 | $10.85M | 20.64% |
| 2013-09-30 | $8.99M | 3.50% |
| 2013-06-30 | $8.69M | -53.40% |
| 2013-03-31 | $18.64M | 119.45% |
| 2012-12-31 | $8.49M | -49.31% |
| 2012-09-30 | $16.76M | -19.75% |
| 2012-06-30 | $20.88M | 1.44% |
| 2012-03-31 | $20.59M | 0.65% |
| 2011-12-31 | $20.45M | -1.62% |
| 2011-09-30 | $20.79M | 0.86% |
| 2011-06-30 | $20.61M | -1.35% |
| 2011-03-31 | $20.90M | -1.39% |
| 2010-12-31 | $21.19M | -23.41% |
| 2010-09-30 | $27.67M | 3.95% |
| 2010-06-30 | $26.62M | 8.36% |
| 2010-03-31 | $24.56M | -7.74% |
| 2009-12-31 | $26.63M | 9.80% |
| 2009-09-30 | $24.25M | -1.43% |
| 2009-06-30 | $24.60M | -1.82% |
| 2009-03-31 | $25.06M | 2.68% |
| 2008-12-31 | $24.40M | -5.17% |
| 2008-09-30 | $25.73M | 7.98% |
| 2008-06-30 | $23.83M | 7.39% |
| 2008-03-31 | $22.19M | 21.72% |
| 2007-12-31 | $18.23M | - |
Alnylam Pharmaceuticals generated $659.83M in revenue during Q2 2024, up 33.48% compared to the previous quarter, and up 206.65% compared to the same period a year ago.
Alnylam Pharmaceuticals Revenue Breakdown
Alnylam Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 18 |
|---|---|---|---|---|---|
| Product | $1.24B | $894.33M | $662.14M | $361.52M | $12.54M |
| GIVLAARI | $219.25M | - | - | - | - |
| Royalty | - | $8.18M | $1.20M | - | - |
Alnylam Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (84.99%), and GIVLAARI (15.01%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Dec 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONPATTRO | $77.24M | $69.22M | $81.59M | $66.53M | $66.66M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GIVLAARI | $62.13M | $58.06M | $165.10M | $54.15M | $11.00M | $5.27M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $410.09M | $365.16M | $346.29M | $313.15M | $305.70M | $276.33M | $261.68M | $232.27M | $213.51M | $186.87M | $198.51M | $167.04M | $160.81M | $135.77M | $112.84M | $99.21M | $26.29M | $12.07M | - | - |
| Royalty | - | - | - | - | $7.21M | $6.50M | $2.71M | $2.74M | $2.28M | $442.00K | $396.00K | $453.00K | $347.00K | - | - | - | - | - | - | - |
Alnylam Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (74.63%), ONPATTRO (14.06%), and GIVLAARI (11.31%).
Alnylam Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Europe | $210.92M | $37.91M | $38.95M | $333.00K | - |
| Non-US Or Europe | $75.77M | $4.17M | $1.76M | $46.75M | - |
| UNITED STATES | $411.17M | $27.70M | $18.88M | $151.57M | $116.45M |
| Non-US | - | - | - | - | $50.09M |
Alnylam Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (58.92%), Europe (30.22%), and Non-US Or Europe (10.86%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US Or Europe | $24.89M | $21.27M | $55.02M | $15.76M | $3.20M | $1.79M | $2.23M | $698.00K | $223.00K | $1.02M | $24.67M | $18.05M | $16.54M | $11.83M | $14.19M | $13.01M | - | - | - | - |
| UNITED STATES | $148.46M | $130.24M | $279.81M | $113.51M | $8.79M | $9.06M | $8.78M | $6.38M | $7.12M | $5.41M | $5.72M | $5.24M | $6.51M | $1.41M | $43.08M | $39.03M | $40.93M | $42.47M | $35.91M | $33.59M |
| Europe | $56.76M | $44.69M | $135.02M | $50.37M | $12.22M | $13.31M | $12.82M | $9.35M | $7.59M | $8.16M | $11.72M | $9.66M | $9.83M | $7.74M | $33.09M | $30.48M | $25.36M | $21.17M | - | - |
| Non-US | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.25M | $8.30M | $20.04M | $12.47M |
Alnylam Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (64.52%), Europe (24.67%), and Non-US Or Europe (10.81%).
Alnylam Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $1.04B |
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| UTHR | United Therapeutics | $2.33B | $714.90M |
| EXEL | Exelixis | $1.83B | $637.18M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| HALO | Halozyme Therapeutics | $829.25M | $231.35M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| WVE | Wave Life Sciences | $113.31M | $19.69M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| PRQR | ProQR Therapeutics | $6.38M | $4.48M |
| KRTX | Karuna Therapeutics | $654.00K | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| MDGL | Madrigal Pharmaceuticals | - | - |
ALNY Revenue FAQ
What is Alnylam Pharmaceuticals’s yearly revenue?
Alnylam Pharmaceuticals's yearly revenue for 2023 was $1.83B, representing an increase of 76.23% compared to 2022. The company's yearly revenue for 2022 was $1.04B, representing an increase of 22.88% compared to 2021. ALNY's yearly revenue for 2021 was $844.29M, representing an increase of 71.31% compared to 2020.
What is Alnylam Pharmaceuticals’s quarterly revenue?
Alnylam Pharmaceuticals's quarterly revenue for Q2 2024 was $659.82M, a 33.48% increase from the previous quarter (Q1 2024), and a 107.00% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $494.33M, a 12.42% increase from the previous quarter (Q4 2023), and a 54.82% increase year-over-year (Q1 2023). ALNY's quarterly revenue for Q4 2023 was $439.72M, a -41.41% decrease from the previous quarter (Q3 2023), and a 31.25% increase year-over-year (Q4 2022).
What is Alnylam Pharmaceuticals’s revenue growth rate?
Alnylam Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 116.55%, and for the last 5 years (2019-2023) was 731.99%.
What are Alnylam Pharmaceuticals’s revenue streams?
Alnylam Pharmaceuticals's revenue streams in c 23 are Product, and GIVLAARI. Product generated $1.24B in revenue, accounting 84.99% of the company's total revenue, up 38.82% year-over-year. GIVLAARI generated $219.25M in revenue, accounting 15.01% of the company's total revenue
What is Alnylam Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Alnylam Pharmaceuticals was Product. This segment made a revenue of $1.24B, representing 84.99% of the company's total revenue.